ENV-294

ENV-294 is a first-in-class, clinical-stage oral small molecule developed by Enveda Biosciences for the treatment of atopic dermatitis and other inflammatory conditions, including asthma. It is designed to address shared inflammatory pathways through a novel, non-steroidal mechanism distinct from kinase inhibition. The drug demonstrates JAK-inhibitor-like efficacy with an improved safety profile similar to IL4/IL13 inhibitors. Its mechanism involves inhibition of the NLRP3/TL1A pathway, targeting key drivers of inflammation implicated in both skin and respiratory diseases. ENV-294 entered Phase 1 clinical trials in late 2024 for atopic dermatitis and has shown promising preclinical results in asthma models[1][2][3][4][5][7].

Other names

ENV 294ENV294ENV-294